Demand to be heard

Article

Kathy LaTour blog image
ovarian cancer advocates

Yesterday morning 180 ovarian cancer advocates walked the three blocks from the hotel where they have been meeting for the 16th Annual Ovarian Cancer National Alliance Meeting to Capitol Hill where they met with their representatives.The women come from across the country and include survivors, mothers, sisters, husbands, aunts, friends and health care professionals. They asked for support for the Cancer Drug Coverage Parity Act (HR1801), which will require "any health plan that provides coverage for cancer chemotherapy treatment to provide coverage for orally administered anticancer medication at a cost no less favorable than the cost of IV, port administered, or injected anticancer medicine." Oral chemotherapy drugs are increasing in number and it's expected they will outnumber other forms of treatment in the coming decade. Twenty-four states and the District of Columbia have already passed oral chemotherapy parity bills, but they do not affect all health plans (Oral Parity Update 2013: State Update).They also asked for $20 million in funds for the Ovarian Cancer Research Project. This project, which is housed in the Department of Defense, allows for what the alliance calls "high-risk high-reward research" that other federal agencies do not have the flexibility to engage in. Already, this project has delivered a new animal model to learn about ovarian cancer, a new treatment using nanoparticles, the discovery of a compound that potentially inhibits cancer growth, and other important information.The ovarian cancer community can't help but compare itself to the breast cancer cause because they have watched as the mortality rate for ovarian has increased while breast cancer mortality has declined. Around 22,000 women will learn they have ovarian cancer this year. Around 15,000 will die. The numbers are not as dramatic as breast cancer, but the percentages speak volumes. Seventy percent of ovarian patients will die from their disease, 25 percent of those diagnosed will die in the first year after diagnosis. They want their lawmakers to know this is not acceptable – and that they vote. You don't have to go the Hill to make an impact on ovarian cancer. You can do it in your community by advocating for yourself and mentoring newly diagnosed women.As one survivor pointed out: There has been progress in disease-free survival but the numbers above have not changed significantly since the Eisenhower administration.

ovarian cancer advocate

Oncology nurse Robin Cohen, Philadelphia; Diane Paul, 20-year survivor advocate, Brooklyn, NY; Peggy Castilho, advocate of Lisa Loonstyh, Philadelphia; Marie Loonstyh, mom of Lisa who died at age 24, Philadelphia; Liz Daley, mother supporting daughter Bre Tipps, Grand Saline, Texas; Michele McAndrews, aunt of Lisa, Philadelphia; Diane Wilson, supporter of Bre Tipps, Grand Saline, Texas; Bre Tipps, diagnosed at age 26, Grand Saline, Texas.

Marie Loonstyh of Philadelphia, whose daughter Lisa died at age 24 from ovarian cancer.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content